Cargando…
SUN-388 Immune Checkpoint Inhibitor Nivolumab in Advanced or Recurrent Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy. Due to the rarity of this malignancy, controlled trials investigating efficacy of chemotherapy or immunotherapy are uncommon. Newer therapy with immune check point inhibitor Nivolumab, a monoclonal antibody of t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553290/ http://dx.doi.org/10.1210/js.2019-SUN-388 |